
|Videos|April 27, 2023
ARVO LIVE: OTT166 in the treatment of diabetic retinopathy
Author(s)David Hutton, Martin David Harp
Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.
Advertisement
Ophthalmology Times® talked with David Tanzer, MD, about OcuTerra Therapeutics and their development of OTT166 in the treatment of diabetic retinopathy.
Video transcript
Editor’s note: Transcript lightly edited for clarity.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
2
Rayner announces Sophi Phaco System in the US
3
FDA grants Fast Track Designation to Complement Therapeutics’ CTx001 for geographic atrophy
4
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
5














































